Top

Gepubliceerd in:

2015 | OriginalPaper | Hoofdstuk

Genetica van atherotrombose

Auteur : Dr. M. P. M. De Maat

Uitgeverij: Bohn Stafleu van Loghum

Abstract

De pathofysiologie van atherotrombose is multifactorieel. De ziekte kent chronische (atherosclerose) en acute (trombose) componenten. Atherosclerose ontwikkelt zich in de intima van grote en middelgrote arteriën. In een gevorderd stadium kunnen er veranderingen optreden in de onderliggende media en adventitia, die tijdens de groei van de plaque kunnen leiden tot vaatwandremodellering en plaqueruptuur. De progressie van atherosclerose is langzaam en het resultaat van veranderingen in een groot aantal fysiologische systemen (lipiden- en koolhydraatstofwisseling, bloeddrukregeling, ontsteking, bloedstolling). Gezamenlijk leiden deze veranderingen tot het ontstaan van disfunctioneel endotheel waarop zich (occluderende) trombi kunnen vormen. Deze kunnen een acuut hart- of herseninfarct veroorzaken. Het zal duidelijk zijn dat vele eiwitten bijdragen aan de regulering van de hierboven genoemde fysiologische processen. In principe kunnen alle genen die coderen voor deze eiwitten afwijkingen bevatten die direct of indirect (via interactie met andere eiwitten en met de omgeving) de ontwikkeling van atherotrombose beïnvloeden (erfelijke risicofactoren). In dit hoofdstuk zal worden besproken in hoeverre variaties in genen die coderen voor eiwitten die betrokken zijn bij de regulering van de trombusvorming bijdragen aan het ontstaan van atherotrombose.

Rosenberg RD, Aird WC. Vascular-bed - specific hemostasis and hypercoagulable states. N Engl J Med 1999;340(20):1555–64.PubMedCrossRef

Mayer B, Erdmann J, Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007;96(1):1–7.PubMedCrossRef

Thordarson O, Fridriksson S. Aggregation of deaths from ischaemic heart disease among first and second degree relatives of 108 males and 42 females with myocardial infarction. Acta Med Scand 1979;205(6):493–500.PubMed

Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330(15):1041–6.PubMedCrossRef

Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986:533–7.

Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258(9):1183–6.PubMedCrossRef

Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341(8854):1165–8.PubMedCrossRef

Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79(1):129–33.PubMed

Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2(8549):3–9.PubMedCrossRef

10.

Crawford DC, Carlson CS, Rieder MJ, Carrington DP, Yi Q, Smith JD, et al. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet 2004; 74(4):610–22.PubMedCrossRef

11.

Bladbjerg EM, de Maat MP, Christensen K, Bathum L, Jespersen J, Hjelmborg J. Genetic influence on thrombotic risk markers in the elderly - a Danish twin study. J Thromb Haemost 2006;4(3):599–607.PubMedCrossRef

12.

Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95(5):1517–32.PubMed

13.

Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001;115(3):491–506.PubMedCrossRef

14.

Voetsch B, Loscalzo J. Genetics of thrombophilia: impact on atherogenesis. Curr Opin Lipidol 2004;15(2):129–43.PubMedCrossRef

15.

Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8(11):1227–34.PubMedCrossRef

16.

Kunicki TJ, Ruggeri ZM. Platelet collagen receptors and risk prediction in stroke and coronary artery disease. Circulation 2001;104(13):1451–3.PubMed

17.

Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case–control study. Circulation 2003;108(24):2971–3.PubMedCrossRef

18.

Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2001;2(4):341–52.PubMedCrossRef

19.

Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998;92(7):2382–8.PubMed

20.

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367(9511):651–8.PubMedCrossRef

21.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, et al. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15(5):427–33.PubMedCrossRef

22.

Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090–4.PubMedCrossRef

23.

Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism Pl(A1)/ Pl(A2) and coronary risk: a meta-analysis. Thromb Haemost 2001;85(4):626–33.PubMed

24.

Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349(9049):385–8.PubMedCrossRef

25.

Plow EF, D’Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost 1992;18(3):324–32.PubMedCrossRef

26.

Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001;5(3):262–87; discussion 311–2.PubMedCrossRef

27.

Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al.Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108(8):989–95.PubMedCrossRef

28.

Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, Zwinderman A, et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008;29(3):375–80.PubMedCrossRef

29.

The Fibrinogen Studies Collaboration. Plasma fibrinogen and the risk of major cardiovascular diseases and non-vascular mortality: meta-analysis of individual data for 154 211 adults in 31 prospective studies. JAMA 2005.

30.

Yang Q Tofler GH, Cupples LA, Larson MG, Feng D, Lindpaintner K, et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res 2003;110(1):57–64.PubMedCrossRef

31.

Verschuur M, de Jong M, Felida L, de Maat MP, Vos HL. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem 2005;280(17):16763–71.PubMedCrossRef

32.

Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, et al. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol 2006;35(4):935–43.PubMedCrossRef

33.

Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008;117(11):1449–59.PubMedCrossRef

34.

Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Circulation 1997;96(4):1102–8.PubMedCrossRef

35.

Rosendaal FR, Varekamp I, Smit C, Brocker-Vriends AH, van Dijck H, Vandenbroucke JP, et al. Mortality and causes of death in Dutch haemophiliacs, 1973–86. Br J Haematol 1989;71(1):71–6.PubMedCrossRef

36.

Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000;20(8):2024–8.PubMedCrossRef

37.

Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111(7): 3540–5.PubMedCrossRef

38.

Bronte-Stewart B, Botha MC, Krut LH. ABO blood groups in relation to ischaemic heart disease. Br Med J 1962;1(5293):1646–50.PubMedCrossRef

39.

Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240(23):2548–52.PubMedCrossRef

40.

Whincup PH, Cook DG, Phillips AN, Shaper AG. ABO blood group and ischaemic heart disease in British men. BMJ 1990;300(6741):1679–82.PubMedCrossRef

41.

Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54–59.PubMedCrossRef

42.

Junker R, Heinrich J, Schulte H, Vandeloo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997;17(8):1539–44.PubMedCrossRef

43.

Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119:119–27.PubMedCrossRef

44.

Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997;17(11):3321–5.PubMedCrossRef

45.

Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994;71:38–48.PubMed

46.

Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, et al. Factor VII gene polymorphism contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996;16:72–6.PubMed

47.

Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arteriosclerosis and Thrombosis 1994;14:193–8.PubMedCrossRef

48.

Iacoviello L, Dicastelnuovo A, Deknijff P, D’Orazio A, Amore C, Arboretti R, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998;338:79–85.PubMedCrossRef

49.

Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the prime study. Thromb Haemost 1998;80(5):749–56.PubMed

50.

Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34(7):457–62.PubMedCrossRef

51.

Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardio - vascular events. Thromb Haemost 1997;78(1):656–60.PubMed

52.

Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635–41.PubMedCrossRef

53.

Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18(1):20–6.PubMedCrossRef

54.

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369(6475):64–7.PubMedCrossRef

55.

Doggen CJM, Cats VM, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998;80(2):281–5.PubMed

56.

Bertina RM. The prothrombin 20210 G to A variation and thrombosis. Curr Opin Hematol 1998;5(5):339–42.PubMedCrossRef

57.

Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357(5):443–53.PubMedCrossRef

58.

de Lange M, Snieder H, Ariens RAS, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001;357(9250):101–5.PubMedCrossRef

59.

Freeman MS, Mansfield MW, Barrett JH, Grant PJ. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 2002;22(3):506–10.PubMedCrossRef

60.

Blangero J, Williams JT, Almasy L. Novel family-based approaches to genetic risk in thrombosis. J Thromb Haemost 2003;1(7):1391–7.PubMedCrossRef

61.

De Maat MPM, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999;83:852–6.PubMedCrossRef

62.

De Maat MPM, Kastelein JJP, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 1998;18:265–71.PubMedCrossRef

63.

Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999;353 (9154):708–12.PubMedCrossRef

64.

O’Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98(12):3256–60.PubMedCrossRef

65.

Aalto-Setala K, Karhunen PJ, Mikkelsson J, Niemela K. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors - the importance of anticoagulants used. J Thromb Thrombolysis 2005; 20(1):57–63.PubMedCrossRef

66.

Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008.

67.

Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta 2007;381(1):26–31.PubMedCrossRef

68.

Remmler C, Cascorbi I. Pharmacogenomics in acute coronary syndrome. Expert Opin Pharmacother 2008;9(3):363–76.PubMedCrossRef

69.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7):2329–33.PubMedCrossRef

70.

Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008;83(3):460–70.PubMedCrossRef

Titel: Genetica van atherotrombose
Auteur: Dr. M. P. M. De Maat
Uitgeverij: Bohn Stafleu van Loghum
DOI: https://doi.org/10.1007/978-90-313-6597-5_5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen